Pulmonary fibrosis following therapy with Melphalan for multiple myeloma

B. W. CODLING AND T. M. H. CHAKERA

From the Department of Pathology, the Medical School, Birmingham, and the Department of Radiology, Queen Elizabeth Hospital, Birmingham

SYNOPSIS A patient suffering from multiple myeloma developed pulmonary fibrosis, of a type known to be associated with busulphan, whilst being treated with Melphalan.

The possible role of Melphalan as the causative agent is discussed. Reference is made to other possible aetiological agents and the reasons for their exclusion are discussed.

Following initial reports of diffuse interstitial fibrosis of the lung resulting from Busulphan therapy for myeloid leukaemia (Oliner, Schwartz, Rubio, and Damasheck, 1961; Leake, Smith, and Woodliff, 1963), the ‘Busulphan lung syndrome’ has become well recognized as a rare but important complication of treatment with Busulphan.

A case showing similar radiological and histological features arising for the first time following therapy with Melphalan for multiple myeloma is now reported.

Case Report

A male patient aged 62 had been treated for five months with methyldopa 250 mg twice a day for hypertension. He was admitted on 18 September 1971 for investigation of a three-month history of backache associated with paraesthesiae of the legs.

A radiological survey of the skeleton showed multiple punched-out areas, especially in the skull and cervical spine, and collapse of the sixth thoracic vertebra.

The erythrocyte sedimentation rate (ESR) was 124 mm in one hr Westergren (normal 0-7 mm in one hr). Serum electrophoresis showed a dense compact band between the $\beta$ and $\gamma$ globulin positions; hypercellular bone marrow aspirate containing large numbers of plasma cells (56.25%) confirmed the diagnosis of multiple myeloma.

Initial treatment was with cyclophosphamide for one week (total dose 1.25 g) plus radiotherapy to the mid-thoracic spine and sternum. This was followed by maintenance therapy of Melphalan 2 mg twice a day and prednisone 10 mg three times a day.

During his first admission to hospital he developed a chest infection with radiographic changes in both lower lobes. This resolved satisfactorily following treatment with ampicillin. At the time of discharge in November he was well and his chest radiograph was clear (Fig. 1).

On 19 December he was admitted as an emergency with a 10-day history of progressive dyspnoea following a ‘chill’.

Fig. 1 Chest radiograph at the time of discharge in November 1971.
Clinical examination revealed dyspnoea at rest and signs of widespread 'consolidation', maximal on the right. His blood pressure was 145/80 mm Hg, and there was no clinical evidence of congestive cardiac failure.

INVESTIGATIONS

Blood count
Haemoglobin 12·4 g/100 ml (100% 14·6 g/100 ml), white blood cells 6 000/cmm (normal 4 000-11 000/cmm), platelets 189 000/cmm (normal 150 000-450 000/cmm), ESR, 107 mm in one hr Westergren. Serum urea 69 mg/100 ml (normal 10-45 mg/100 ml).

Blood gases
PCO₂ 46 mm Hg (normal 35-45 mm Hg), PO₂ 54 mm Hg (normal 80-100 mm Hg), pH 7·48 (normal 7·38-7·44), and standard bicarbonate 32·5 m equiv/l (normal 22-26 m equiv/l).

Bacteriology
Sputum yielded a moderate growth of normal commensals sensitive to the antibiotic therapy being given (ampicillin).

Treatment with Melphalan was stopped and prednisolone substituted for the prednisone, initially 30 mg twice daily decreasing to 20 mg twice a day over a period of five days.

A chest radiograph now showed widespread fine nodular (0·5-1·00 mm) and linear opacities involving both lungs diffusely but most striking in the upper zones and perihilar regions. In addition there was elevation of the lesser fissure suggesting loss of volume of the right upper lobe.

The heart was not enlarged (transverse diameter 14·0 cm, normal up to 15·5 cm), the same size as on the first admission, and there were no septal lines to suggest congestive cardiac failure (Fig. 2).

Multiple rib fractures were also noted on the radiograph.

Despite treatment with steroids and antibiotics his condition progressively deteriorated. The dyspnoea increased and there was marked arterial oxygen desaturation with hypercapnia and terminal rise in blood urea (highest value recorded 151 mg/100 ml) before he died on 2 January 1972.

Postmortem Findings

The major findings at necropsy were confined to the respiratory system and skeleton, which showed widespread involvement with multiple myeloma. Changes in the cardiovascular system consistent with moderate systemic hypertension were present (heart weight 410 g, normal up to 340 g, left ventricle 1·6 cm thick (normal up to 1·4 cm)). The right ventricle showed no evidence of hypertrophy.

The pleurae were normal. Small, clear, bilateral effusions were present. Both lungs retained their shape on removal from the chest and were firmer than normal. The right lung on section showed a variegated grey and yellowish appearance, with areas of haemorrhage. The left lung was fixed inflated by infusion of formol saline into the bronchial tree. When fixed the lung was cut into 1 cm thick serial slices. The cut surface showed a solid appearance with obliteration of many alveoli by fibrous tissue and with dilatation of alveoli and alveolar ducts. Progression to an early honeycomb pattern in some areas (Fig. 3) was seen with abnormal air spaces measuring up to 2 mm in diameter (normal alveoli 250-350 μ diameter and alveolar ducts up to 470 μ in diameter).

Histology

There was extensive involvement of bone marrow by deposits of myeloma.

The lungs showed proliferation of alveolar lining cells. These appeared as large eosinophilic cells with abundant granular cytoplasm, large vesicular...
Fig. 3 1 cm slice from the mid portion of left lung. Inset, a close up of the anterior part of the upper lobe.

Fig. 4 Alveolus containing hyperplastic alveolar lining cells with giant cells. The alveolus also contain fibrinous exudate. H. & E. × 520.
Pulmonary fibrosis following therapy with Melphalan for multiple myeloma

Fig. 5 Terminal bronchiole showing hyperplastic epithelium. H. & E. × 195.

Fig. 6 Alveoli containing fibrinous exudate with hyperplastic lining cells also. H. & E. × 195.

Fig. 7 Obliteration of alveoli by fibrous tissue. H. & E. × 195.
nuclei with prominent nucleoli, and giant cell formation (Fig. 4).

There was also proliferation of the epithelial lining cells of terminal bronchioles (Fig. 5). In some areas this proliferating epithelium formed clumps of cells surrounded by fibrous tissue and bearing a superficial resemblance to the 'tumourlets' seen in bronchiectasis.

The alveoli contained a fibrinous exudate (Fig. 6) showing organization by fibrous tissue with obliteration of air spaces (Fig. 7). Interstitial fibrosis was also present and in addition there was a chronic inflammatory cell infiltrate consisting mainly of normal plasma cells. There was no histological evidence of pulmonary hypertension.

Discussion

The lung changes in the present case are the same as those described as complicating busulphan therapy. The changes associated with busulphan therapy, together with similar reactions following severe left ventricular failure, uraemia, nitrofurantoin therapy, and therapy with hexamethonium and related ganglion-blocking agents, have been reviewed by Kirschner and Esterly (1971). Other factors associated with similar pulmonary changes include irradiation (Smith, 1963), intermittent positive pressure ventilation (Hall and Margolin, 1972), and bleomycin therapy (Fleischman, Baker, Thompson, Schaeppi, Illievski, Cooney, and Davis, 1971). The features of this patient's illness which had to be considered as possible causes of the pulmonary disorder were irradiation, myeloma infiltration, uraemia, methyldopa, cyclophosphamide, and Melphalan.

It is difficult to assess accurately the effects of irradiation in this case. The patient received a total of 3 000 rads (skin dose) in 10 fractions over 14 days from a 230 KV unit.

The fields irradiated were 10 × 12 cm posteriorly to the mid thoracic vertebrae and 12 × 15 cm anteriorly to the sternum. The calculated total central mediastinal dose (antero-posterior diameter 24 cm) was 1320 rads. This dose is below that generally recognized as causing radiation fibrosis (Jennings and Arden, 1962). Moreover the radiological and histological changes described were not, in this case, confined to the narrow, central irradiated area.

Myeloma infiltration of the lung is well documented (Gabriel, 1965). The present case showed no evidence of pulmonary involvement and plasma cells in the inflammatory infiltrate were present in similar numbers to those noted in a case of busulphan lung (Rushton, 1972).

Doubt has been cast on the role of hexametho-
to a product of the disintegrating type II pneumocyte.

In the present situation Melphalan may be important in inhibiting the removal of intraalveolar debris by its toxic effect on phagocytes.

We thank Dr G. E. Owen Williams for permission to publish the clinical details of this case, Dr G. A. Newsholme and Professor D. B. Brewer for their help in the preparation of the manuscript, and Miss G. L. Parkinson for typing the manuscript.

Requests for reprints should be addressed to B. W. Codling, Department of Pathology, Medical School, University of Birmingham, P. O. Box 363, Edgbaston, Birmingham B15 2TJ, England.

References


Pulmonary fibrosis following therapy with Melphalan for multiple myeloma
B. W. Codling and T. M. H. Chakera

doi: 10.1136/jcp.25.8.668

Updated information and services can be found at:
http://jcp.bmj.com/content/25/8/668

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/